75
Views
11
CrossRef citations to date
0
Altmetric
Special Report

Cost effectiveness of methylphenidate versus AMP/DEX mixed salts for the first-line treatment of ADHD

&
Pages 625-634 | Published online: 09 Jan 2014

References

  • Robison LM, Sclar DA, Dkaer TL. National trends in the prevalence of attention-deficit/hyperactivity disorder and the prescribing of methylphenidate among school-age children: 1990–1995. Clin. Fed. 38(4), 209–217 (1999).
  • Rowland AS, Umbach DM, Stallon L. Prevalence of medication treatment for attention deficit-hyperactivity disorder among elementary school children in Johnston County, North Carolina. Am. J Public Health 92(2), 231–234 (2002).
  • AACAP Official Action. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. J Am. Acad. Child. Psych. 36\(Suppl. 10), 85–121 (1997).
  • American Academy of Pediatrics. Committee on quality improvement, subcommittee on attention-deficit/hyperactivity disorder. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics 105(5), 1158–1170 (2000).
  • Kelleher KJ, Childs GE, Harman JS. Healthcare costs for children with attention-deficit/hyperactivity disorder. TEN3(4), 60–63 (2001).
  • Attention deficit disorder and learning disability, United States, 1997-1998. CDC Vital and health statistics. 10,206 (2002).
  • Perrin JM, Stein MT, Amler RW. Clinical Practice Guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 108(4), 1–20 (2001).
  • Pliszka SR, Greenhill LL, Crisman ML. The Texas children's medication algorithm project: report of the Texas consensus conference panel on medication treatment of childhood attention-deficit/hyperactivity disorder. Part II: tactics. J Am. Acad. Child. Adolesc. Psych. 39(7), 920–927 (2000).
  • Elia J, Borcherding BG, Rapoprt JL. Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true nonresponders? Psychiatry Res. 36, 141–155 (1991).
  • Zametkin AJ, Ernst M. Problems in the management of attention-deficit-hyperactivity disorder. N Engl. J. Med. (340)1, 40–46 (1999).
  • Spencer TJ, Biederman J, Wilens TE. Novel treatments for attention-deficit/hyperactivity disorder in children. Clin. Psych. 63 (Suppl. 12) 16–22 (2002).
  • Milne R, Stein K. Methylphenidate in children with hyperactivity. Wessex Institute Development and Evaluation Committee Report. 78 (1998).
  • ••Only study available that converts thebenefit attained from treatment into utility scores and weighs it agains the cost.
  • Conners CK, Epstein JN, March JS. Multimodal treatment of ADHD in the MTA: an alternative outcome analysis. J. Am. Acad. Child. Adolesc. Psych. 40(2) 159–167 (2001).
  • Leibson CL, Katusic SK, Barbaresi WJ. Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder. JAMA 285(1), 53–66 (2001).
  • ••Valuable assessment of attention deficithyperactivity disorder (ADHD) in the US context.
  • Chan E, Zhan C, Homer CJ. Healthcare use and costs for children with attention-deficit/hyperactivity disorder: national estimates from the medical expenditure panel survey. Arch. Pediatr. Adolesc. Med. 156,504-511 (2002).
  • Marchetti A, Magar R, Lau H. Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis. Clin. Ther 23(11), 1904-1920 (2001).
  • Pliszka SR, Browne RG, Olvera RL. A double-blind, placebo-controlled study of adderall and methylphenidate in the treatment of attention-deficit/hyperactivity disorder. J. Am. Acad. Child. Adolesc. Psych. 39(5), 1–12 (2000).
  • Pelham WE, Gnagy E, Chronis A. A comparison of morning-only and morning/late afternoon adderall to morning-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 104(6), 1300–1311 (1999).
  • Pelham WE, Aronoff HR, Midlam JK. A comparison of Ritalin and Adderall: efficacy and time-course in children with attention-deficit/hyperactivity disorder. Pediatrics 103 (4), 1–14 (1999).
  • Landgraf JM, Rich M, Rappaport L. Measuring quality of life in children with attention-deficit/hyperactivity disorder and their families: development and evaluation of a new tool. Arch. Pediatr. Adolesc. Med. 156,384-391 (2002).
  • ••Key contribution to the measurement ofquality of life in pediatric ADHD patients and their families.
  • Gilmore A, Milne R. Methylphenidate in children with hyperactivity: review and cost-utility analysis. Pharmacoepidemiol. Drug Safety 10,85–94 (2001).
  • Guevara J, Lozano P, Wickizer T. Utilization and cost of healthcare services for children with attention-deficit/hyperactivity disorder. Pediatrics 108(1), 71–78 (2001).
  • Swensen AR, Birnbaum HG, Secnik K et al. Attention-deficit/hyperactivity disorder: increased costs for patients and their families. J. Am. Acad. Child. Adolesc. Psych. 42(12), 1415–1423 (2003).
  • Gillberg C, Melander H, von Knorring AL. Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms: a randomized, double-blind, placebo-controlled trial. Arch. Gen. Psych. 54 (9), 857–864 (1997).
  • Pelham WE, Gnagy EM, Burrows A. Once-a-day concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 107(6), 1–28 (2001).
  • Kuhne M, Schachar R, Tannock R. Impact of comorbid oppositional or conduct problems on attention-deficit hyperactivity disorder. J. Am. Acad. Child. Adolesc. Psych. 36(12), 1715–1725 (2001).
  • Pelham WE, Carlson C, Sams SE. Separate and combined effects of methylphenidate and behavior modification on the classroom behavior and academic performance of ADHD boys: group effects and individual differences. J Consult. Clin. Psychol. 61, 506–515 (1993).
  • Barkley RA. Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder. Clin. Psych. 63 (Suppl. 12), 10–15 (2002).
  • Grcevich S, Rowane WA, Marcellino B. Retrospective comparison of adderall and methylphenidate in the treatment of attention deficit hyperactivity disorder. J Child. Adolesc. Psychopharmacol. 11(1), 35–41 (2001).
  • Millor A, Lee SK, Raina P A review of therapies for attention-deficit/hyperactivity disorder. Report by the Canadian co-ordinating office of health technology assessment (CCOHTA). RFP#ADHD-1196 (1998).
  • Lord J, Paisley S. The clinical effectiveness and cost effectiveness of methylphenidate for hyperactivity in childhood. Report by National Institute for Clinical Excellence, London, UK (2000).
  • ••Comprehensive assessment of ADHDtherapy cost effectiveness in the British context.
  • Wilens T, Pelham W, Stein M. ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study. J Am. Acad. Child. Adolesc. Psych. 42 (4), 424–433 (2002).
  • Sawyer MG, Whaites L, Rey JM. Health- related quality of life of children and adolescents with mental disorders. J Am. Acad. Child. Adolesc. Psych. 41 (5), 530–537 (2003).
  • First Databank. Price Probe. Updated May 7,2003 (2003).
  • Biederman J, Lopez FA, Boellner SW A randomized, double-blind, placebo-controlled, parallel-group study of 5LI381 (AdderallXR) in children with attention-deficit/hyperactivity disorder. Pediatrics 110(2), 258–266 (2002).
  • James RS, Sharp WS, Bastain TM. Double- blind, placebo-controlled study of single-dose amphetamine formulations in ADHD. J Am. Acad. Adolesc. Psych. 40(11), 1268–1276 (2001).
  • Spencer T, Biederman J, Wilens T. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch. Gen. Psych. 58(8), 775–782 (2001).
  • Wolraich MI, Greenhill LL, Pelham W Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit /hyperactivity disorder. Pediatrics 108(4), 883–892 (2001).
  • Klein RG, Wender P. The role of methylphenidate in psychiatry. Arch. Gen. Psych. 52(6), 429–433 (1995).
  • The MTA Co-operative Group. A 14-month randomizedc clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch. Gen. Psych. 56(12), 1073–1086 (1999).
  • Golinko BE. Side effects of dextroamphetamine and methylphenidate in hyperactive children — a brief review. Frog. Neuro-Psychopharmacol. Biol. Psych. a(8), 1–8 (1984).

Website

  • Bureau of Labor Statistics www.b1s.gov (Accessed November 2004)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.